Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIVmac239

PLoS Pathogens

Volumn 5, Issue 1, 2009, Pages

  Jia, Bin ^a   Ng, Sharon K ^a   DeGottardi, M Quinn ^a   Piatak Jr , Michael ^b   Yuste, Eloísa ^a,e   Carville, Angela ^a   Mansfield, Keith G ^a   Li, Wenjun ^c   Richardson, Barbra A ^d   Lifson, Jeffrey D ^b   Evans, David T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS GLYCOPROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPERIMENTAL MONKEY; HELPER CELL; IMMUNE RESPONSE; INOCULATION; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; NONHUMAN; RHESUS MONKEY; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANIMAL DISEASE; BLOOD; CD8+ T LYMPHOCYTE; IMMUNIZATION; IMMUNOLOGY; MACACA; METHODOLOGY; MONKEY DISEASE; VESICULAR STOMATITIS VIRUS; VIROLOGY;

ANIMALIA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNIZATION; MACACA MULATTA; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULOVIRUS; VIRAL LOAD;

EID: 59249098162     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000272     Document Type: Article

References (84)

1. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live-attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
2. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. Journal of Virology 73: 8356-8363.
3. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC (1996) Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. Journal of Virology 70: 3724-3733.
4. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820-1824.
5. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Medicine 5: 194-203.
6. Wyand MS, Manson KH, Lackner AA, Desrosiers RC (1997) Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nature Medicine 3: 32-36.
7. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, et al. (2003) Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. Journal of Virology 77: 6823-6835.
8. Amara RR, Villinger R, Altman JD, Lydy SL, O'Neil SP, et al. (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
9. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu T-M, et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
10. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, et al. (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106: 539-549.
11. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
12. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, et al. (2002) Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. Journal of Virology 76: 7187-7202.
13. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang Z-Q, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. Journal of Virology 79: 15547-15555.
14. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, et al. (2006) Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. Journal of Virology 80: 5875-5885.
15. Hel Z, Tsai W-P, Tryniszewska E, Nacsa J, Markham PD, et al. (2005) Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. Journal of Immunology 176: 85-96.
16. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312: 1530-1533.
17. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, et al. (2006) Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. Journal of Experimental Medicine 203: 1533-1541.
18. Steinbrook R (2007) One step forward, two steps back - ill there ever be an AIDS vaccine? New England Journal of Medicine 357: 2653-2655.
19. Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? Journal of Experimental Medicine 205: 7-12.
20. Lifson JD, Martin MA (2002) One step forwards, one step back. Nature 415: 272-273.
21. Feinberg MB, Moore JP (2002) AIDS vaccine models: Challenging challenge viruses. Nature Medicine 8: 207-210.
22. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature Medicine 14: 617-621.
23. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, et al. (2008) HIV vaccine research: the way forward. Science 321: 530-532.
24. Cohen J (2008) Thumbs down on expensive, hotly debated trial of NIH AIDS vaccine. Science 321: 472.
25. Evans DT, Bricker JE, Desrosiers RC (2004) A novel approach for producing lentiviruses that are limited to a single cycle of infection. Journal of Virology 78: 11715-11725.
26. Jia B, DeGottardi MQ, Evans DT (2006) Single-cycle SIV: a novel AIDS vaccine approach. Future Virology 1: 747-758.
27. Kuate S, Stahl-Hennig C, Haaft Pt, Heeney J, Uberla K (2003) Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. Virology 313: 653-662.
28. Evans DT, Bricker JE, Sanford HB, Lang S, Carville A, et al. (2005) Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. Journal of Virology 79: 7707-7720.
29. Kuate S, Stahl-Hennig C, Stoiber H, Nchinda G, Floto A, et al. (2006) Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 351: 133-144.
30. Kaech S, Wherry J, Ahmed R (2002) Effector and memory T-cell differentiaion: implications for vaccine development. Nature Reviews Immunology 2: 251-262.
31. Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunology 2: 415-422.
32. DeGottardi MQ, Lew SK, Piatak M, Jia B, Feng Y, et al. (2008) Comparison of plasma viremia and antibody responses in macaques inoculated with envelope variants of single-cycle SIV differing in infectivity and cellular tropism. Journal of Virology 82: 321-334.
33. Picker LJ, Hagen SI, Lum R, Reed-Inderbitzin EF, Daly LM, et al. (2004) Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. Journal of Experimental Medicine 200: 1299-1314.
34. Mori K, Ringler DJ, Kodama T, Desrosiers RC (1992) Complex determinants of macrophage tropism in env of simian immunodeficiency virus. Journal of Virology 66: 2067-2075.
35. Yuste E, Reeves J, Doms R, Desrosiers R (2004) Modulation of Env content in virions of simian immunodeficiency virus: Correlation with cell surface expression and virion infectivity. Journal of Virology 78: 6775-6785.
36. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC (2005) Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. Journal of Virology 79: 12455-12463.
37. Swigut T, Iafrate AJ, Muench J, Kirchhoff F, Skowronski J (2000) Simian and human immunodeficiency virus nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression. Journal of Virology 74: 5691-5701.
38. Swigut T, Alexander L, Morgan J, Lifson J, Mansfield KG, et al. (2004) Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. Journal of Virology 78: 13335-13344.
39. Rose NF, Roberts A, Buonocore L, Rose JK (2000) Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficieny virus type 1. Journal of Virology 74: 10903-10910.
40. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, et al. (1999) Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Medicine 5: 211-216.
41. Zhang L, Dailey PJ, Gettie A, Blanchard J, Ho DD (2002) The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys. Journal of Virology 76: 5271-5273.
42. Zhang L, Dailey PJ, He T, Gettie A, Bonhoeffer S, et al. (1999) Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. Journal of Virology 73: 855-860.
43. Means RE, Greenough T, Desrosiers RC (1997) Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. Journal of Virology 71: 7895-7902.
44. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PWHI, et al. (2003) Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. Journal of Virology 77: 9993-10003.
45. Gauduin M-C, Kaur A, Ahmad S, Yilma T, Lifson JD, et al. (2004) Optimization of intracellular cytokine staining for the quantitation of antigen-specific CD4+ T cell responses in rhesus macaques. Journal of Immunological Methods 288: 61-79.
46. Douek DC, Brenchley JM, Betts MR, Abrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98.
47. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD (1998) Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279: 1223-1227.
48. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nature Medicine 4: 679-684.
49. Mansfield K, Lang SM, Gauduin M-C, Sanford HB, Lifson JD, et al. (2008) Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. Journal of Virology 82: 4135-4148.
50. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nature immunology 7: 19-23.
51. Parren PWHI, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of Virology 75: 8340-8347.
52. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 6: 207-210.
53. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Medicine 6: 200-206.
54. Hessel AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-105.
55. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 342: 921-929.
56. Kuroda MJ, Schmitz JE, Barouch DH, Craiu A, Allen TM, et al. (1998) Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. Journal of Experimental Medicine 187: 1373-1381.
57. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, et al. (1999) HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine 5: 518-525.
58. Gauduin MC, Glickman RL, Ahmad S, Yilma T, Johnson RP (1999) Characterization of SIV-specific CD4+ T-helper proliferative responses in macaques immunized with live-attenuated SIV. J Med Primatol 28: 233-241.
59. Gauduin M-C, Yu Y, Barabasz A, Carville A, Piatak M, et al. (2006) Induction of a virus-specific effector-memory CD4+ T cell responses by attenuated SIV infection. Journal of Experimental Medicine 203: 2661-2672.
60. Day CL, Walker BD (2003) Progress in defining CD4 helper cell responses in chronic viral infections. Journal of Experimental Medicine 198: 1773-1777.
61. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. Journal of Experimental Medicine 188: 205-2213.
62. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003: 337-339.
63. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
64. Matloubian M, Concepcion RJ, Ahmed R (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. Journal of Virology 68: 8056-8063.
65. Janssen EM, Lemmens EE, Wolfe T, Christen U, Herrath MGv, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856.
66. Rollman E, Smith MZ, Brooks AG, Purcell DFJ, Zuber B, et al. (2007) Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: Implications for HIV vaccine strategies. Journal of Immunology 179: 4571-4579.
67. Almond N, Rose J, Sangster R, Silvera P, Stebbings R, et al. (1997) Mechanisms of protection induced by attenuated simian immundeficiency virus. I. Protection cannot be transferred with immune serum. Journal of General Virology 78: 1919-1922.
68. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, et al. (1998) Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. Journal of Virology 72: 7501-7509.
69. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, et al. (1997) Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. Journal of Virology 71: 5069-5079.
70. Mothe BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, et al. (2003) Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. Journal of Virology 77: 2736-2740.
71. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, et al. (2004) Cytotoxic T lymphocyte-based contol of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. Journal of Experimental Medicine 199: 1709-1718.
72. Stahl-Hennig C, Kuate S, Franz M, Suh YS, Stoiber H, et al. (2007) Atraumatic oral spray immunization with replication-deficient viral vector vaccines. Journal of Virology 81: 13180-13190.
73. Hernandez RD, Hubisz MJ, Wheeler DA, Smith DG, Ferguson B, et al. (2007) Demographic histories and patterns of linkage disequilibrium in Chinese and Indian rhesus macaques. Science 316: 240-243.
74. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, et al. (2002) SIVmac pathogenesis in rhesus macaques of Chinese and Indian orgin compared with primary HIV infections in humans. AIDS 16: 1489-1496.
75. Marthas ML, Lu D, Penedo MCT, Hendrickx AG, Miller CJ (2001) Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Research and Human Retroviruses 17: 1455-1466.
76. Anonymous (1996) The Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and Use of Laboratory Animals. pp 86-123.
77. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, et al. (2006) The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. Journal of Virology 80: 5074-5077.
78. Wojcechowskyj JA, Yant LJ, Wiseman RW, O'Connor SL, O'Connor DH (2007) Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes. Journal of Virology 81: 406-410.
79. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, et al. (2007) Mamu-B*08-positive macaques control simian immunodeficiency virus replication. Journal of Virology 81: 8827-8832.
80. Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, et al. (2007) Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59: 693-703.
81. ArthurARaHRO, Bess JW, Chertova EN, Rossio JL, Esser MT, et al. (1998) Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine. AIDS Research and Human Retroviruses 14: S311-S319.
82. Alexander L, Veazey RS, Czajak S, DeMaria M, Rosenzweig M, et al. (1999) Recombinant simian immunodeficiency virus expressing green fluorescent protein identifies infected cells in rhesus monkeys. AIDS Research and Human Retroviruses 15: 11-21.
83. Cline AN, Bess JW, Piatak M, Lifson JD (2005) Highly sensitive SIV plasma viral load assay: Practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. Journal of Medical Primatology 34: 303-312.
84. Diggle PJ, Heagerty P, Liang KY, Zeger SL (2002) Analysis of longitudinal data. New York: Oxford University Press.